Local and systemic effects of inhaled AZD9164 compared with tiotropium in patients with COPD.

  title={Local and systemic effects of inhaled AZD9164 compared with tiotropium in patients with COPD.},
  author={L. Bjermer and T. Bengtsson and C. Jorup and J. L{\"o}tvall},
  journal={Respiratory medicine},
  volume={107 1},
  • L. Bjermer, T. Bengtsson, +1 author J. Lötvall
  • Published 2013
  • Medicine
  • Respiratory medicine
  • There is still a need for new agents which improve upon the therapeutic index of tiotropium, the current standard of care for many patients with chronic obstructive pulmonary disease (COPD). We examined in patients with COPD the efficacy of single doses of AZD9164, an M(3)-selective muscarinic antagonist, to identify an appropriate dose-range for future studies. COPD patients (n = 28) inhaled AZD9164 (100, 400 and 1200 μg), tiotropium (18 μg) and placebo at 5 study centre visits (Clinicaltrials… CONTINUE READING
    9 Citations
    Muscarinic receptor antagonists for the treatment of chronic obstructive pulmonary disease
    • 24
    Long-Acting Muscarinic Antagonists Under Investigational to Treat Chronic Obstructive Pulmonary Disease
    • PDF
    Muscarinic Receptor Antagonists.
    • 13
    Novel anti-cholinergics in COPD.
    • 10


    A 4-year trial of tiotropium in chronic obstructive pulmonary disease.
    • 1,504
    • PDF
    The pharmacological properties of tiotropium.
    • 204
    Muscarinic receptor signaling in the pathophysiology of asthma and COPD
    • 320
    • PDF
    Cholinergic pathways in the lungs and anticholinergic therapy for chronic obstructive pulmonary disease.
    • K. E. Belmonte
    • Medicine
    • Proceedings of the American Thoracic Society
    • 2005
    • 185
    Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary.
    • 10,883
    • PDF
    Protective effects of tiotropium bromide in the progression of airway smooth muscle remodeling.
    • 194
    • PDF
    The discovery of AZD9164, a novel muscarinic M3 antagonist.
    • 15